FDA Brief

Warning letters Drugs

FDA warning letter to

KDunn and Associates, P.A. dba HealthQuilt

High riskIssued Feb 16, 2021Posted Mar 2, 2021Center for Drug Evaluation and Research | CDER

Houston research sponsor ran a COVID-19 drug study on people without an FDA-approved application or proper consent forms.

What happened

FDA inspected KDunn and Associates (doing business as HealthQuilt) in Houston, Texas, from August 4 to August 13, 2020, as part of its program that inspects research to protect human subjects. FDA found the company sponsored a study of an unapproved drug in people who had tested positive for COVID-19 or were close contacts of such people, without first filing an Investigational New Drug application (IND — the FDA permission needed before testing a drug in people). FDA also found no shipping or receipt records for the drug, consent forms that made subjects give up their right to sue, and at least eight consent forms that were not kept after the study ended.

What FDA found

  1. The company tested a drug in people without first submitting an IND to FDA, even though the drug was not lawfully marketed and did not qualify for an exemption.

    21 CFR 312.20(a), 312.20(b), 312.40(a)
  2. The company kept no records showing receipt, shipment, or other movement of the study drug.

    21 CFR 312.57(a)
  3. The consent form told subjects to waive their legal rights and release the sponsor, investigator, and drug maker from liability for negligence.

    21 CFR 312.60 and 21 CFR 50.20
  4. The investigator did not keep at least eight signed and dated consent forms for the required two years after the study was discontinued on July 23, 2020.

    21 CFR 312.62(c)

What FDA wants

FDA asks the company to write back within 15 working days describing the actions taken to prevent these violations, or to explain why it believes it is already in compliance and to supply supporting information.

Who should pay attention

  • sponsors and investigators running clinical trials of unapproved products
  • institutional review boards and research compliance staff
  • companies that supply study drugs and consent form templates

This is a summary. Read the original letter on fda.gov.

Similar letters to other companies

  1. Center For Immunology Science, LLC

    FDA cites Center for Immunology Science for a clinical trial of heat-killed Mycobacterium smegmatis without an Investigational New Drug application.

    High risk
  2. Prodrome Sciences USA, LLC

    Prodrome Sciences studied its supplement ProdromeNeuro Oil as a dementia drug in 29 people without first filing an IND, FDA says.

    High risk
  3. Pamela K. Den Besten, DDS, MS

    FDA warned sponsor-investigator Pamela K. Den Besten for running a pediatric dental gel study without an IND, enrolling 43 subjects.

    High risk
  4. MG Infusions

    FDA warned MG Infusions it sells unlicensed fecal transplant products online without required approval.

    High risk